Skip to main content
Premium Trial:

Request an Annual Quote

Bringing It Back

Biogen is seeking to resurrect an Alzheimer's disease drug from a trial it discontinued earlier this year, as Time magazine reports.

The drug, aducanumab, appeared in early studies to both decrease the amount of amyloid protein that accumulates in Alzheimer's patients' brains and limit cognitive decline. But Biogen terminated trials it was conducted after an early analysis indicated that the results were not a promising as hoped, Time adds. But now after delving further into the full data, the company is seeking approval for aducanumab from the US Food and Drug Administration.

As Time reports, Biogen found when it looked through the data again that one of its two trials did show that the treatment might have been influencing cognitive decline. The firm traced the difference between the trials to a change it made to the study design, namely that in one, people with alterations in the ApoE gene were given lower doses of the drug, it says. As the Wall Street Journal notes, patients with that genetic variant who were given a higher does experienced less cognitive decline.

"If approved, this drug would make Alzheimer's disease a treatable condition, from a biological point of view. This would be major league," Steven Salloway tells Time.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.